Eli Lilly & Co logo

Eli Lilly & Co (LLY)

Market Closed
13 May, 20:00
670. 00
-14.7
-2.15%
- Market Cap
104.2 P/E Ratio
5.2% Div Yield
2,141 Volume
6.64 Eps
684.7
Previous Close
Day Range
668.4 684.8
Year Range
616.9 888.8

Summary

LLY closed today lower at €670, a decrease of 2.15% from yesterday's close, completing a monthly decrease of -5.27% or €37.3. Over the past 12 months, LLY stock lost -10.32%.
LLY pays dividends to its shareholders, with the most recent payment made on Mar 10, 2025. The next announced payment will be in In 3 weeks on Jun 10, 2025 for a total of €1.5.
The last earnings report, released on May 01, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

LLY Chart

Why Lilly (LLY) International Revenue Trends Deserve Your Attention

Why Lilly (LLY) International Revenue Trends Deserve Your Attention

Examine Lilly's (LLY) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Zacks | 11 hours ago
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.

Wsj | 1 day ago
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (May 2025)

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (May 2025)

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.

247wallst | 1 day ago

Eli Lilly & Co (LLY) FAQ

What is the stock price today?

The current price is €670.00.

On which exchange is it traded?

Eli Lilly & Co is listed on NYSE.

What is its stock symbol?

The ticker symbol is LLY.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Eli Lilly & Co ever had a stock split?

No, there has never been a stock split.

Eli Lilly & Co Profile

Drug Manufacturers—General Industry
Healthcare Sector
Mr. David A. Ricks CEO
XFRA Exchange
US5324571083 ISIN
United States Country
43,000 Employees
14 Feb 2025 Last Dividend
16 Oct 1997 Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center
Phone: 317 276 2000